Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease

2014292 citationsJournal Articlehybrid Open Access

Authors

Icíar Avilés-Olmos · Sobell House

John Dickson · University College London Hospitals NHS Foundation Trust

Zinovia Kefalopoulou · Sobell House

Atbin Djamshidian

Joshua Kahan · Sobell House

Peter J. Ell · University College London Hospitals NHS Foundation Trust

Peter S. Whitton · The London College

Abstract

While these data must still not be interpreted as evidence of neuroprotection, they nevertheless provide strong encouragement for the further study of this drug as a potential disease modifying agent in Parkinson's disease.

Topics & Keywords

Parkinson's Disease Mechanisms and Treatments Neurological disorders and treatments Autism Spectrum Disorder Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Parkinson s Disease

Volume 4, Issue 3, pp. 337-344

DOI: 10.3233/jpd-140364

Field-Weighted Citation Impact: 18.18